$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000032001716000115 Filed on May 05, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$8.300M	$7.489M	$3.172M
YoY Change	41.48%	136.09%	78112.01%
Cost Of Revenue	$7.052M	$6.228M	$3.369M
YoY Change	21.6%	84.89%	-11.94%
Gross Profit	$1.249M	$1.261M	-$196.3K
YoY Change	1732.11%	-742.37%	-94.86%
Gross Profit Margin	15.05%	16.84%	-6.19%
Selling, General & Admin	$2.917M	$6.458M	$11.09M
YoY Change	-66.61%	-41.75%	23.61%
% of Gross Profit	233.58%	512.09%
Research & Development	$4.489M	$5.876M	$6.804M
YoY Change	-40.95%	-13.63%	42.96%
% of Gross Profit	359.41%	465.93%
Depreciation & Amortization	-$490.0K	$740.0K	$600.0K
YoY Change	-175.38%	23.33%	36.36%
% of Gross Profit	-39.23%	58.68%
Operating Expenses	$7.406M	$18.56M	$21.26M
YoY Change	-76.52%	-12.69%	21.11%
Operating Profit	-$7.406M	-$11.07M	-$18.09M
YoY Change	-71.15%	-38.78%	33.99%
Interest Expense	$335.9K	$926.8K	$551.0K
YoY Change	-38.63%	68.22%	485.16%
% of Operating Profit
Other Income/Expense, Net	-$327.1K	-$921.1K	-$1.097M
YoY Change	-106.8%	-16.03%	286.66%
Pretax Income	-$7.733M	-$11.99M	-$19.18M
YoY Change	-62.93%	-37.48%	39.2%
Income Tax	$0.00	$53.38K	$46.63K
% Of Pretax Income
Net Earnings	-$7.885M	-$12.05M	-$19.19K
YoY Change	45939.76%	62691.45%	40.24%
Net Earnings / Revenue	-94.99%	-160.86%	-0.6%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.325M	-$2.041M	-$5.104M
COMMON SHARES
Basic Shares Outstanding	59.03M shares	59.03M shares	38.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.70M	$25.40M	$19.13M
YoY Change	-54.87%	32.77%	-53.79%
Cash & Equivalents	$10.34M	$25.43M	$19.13M
Short-Term Investments			$0.00
Other Short-Term Assets	$8.600M	$7.600M	$7.900M
YoY Change	22.86%	-3.8%	139.39%
Inventory
Prepaid Expenses
Receivables	$2.892M	$2.613M	$1.969M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$29.25M	$35.62M	$29.02M
YoY Change	-38.38%	22.74%	-37.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.04M	$16.92M	$15.85M
YoY Change	1.36%	6.76%	14.95%
Goodwill	$7.013M	$7.013M	$25.21M
YoY Change	-72.18%	-72.18%	126.75%
Intangibles	$2.593M	$2.735M	$47.41M
YoY Change	-93.15%	-94.23%	245.44%
Long-Term Investments
YoY Change
Other Assets	$812.9K	$894.5K	$1.325M
YoY Change	-36.06%	-32.49%	9.99%
Total Long-Term Assets	$27.46M	$27.57M	$89.80M
YoY Change	-66.16%	-69.3%	125.4%
TOTAL ASSETS
Total Short-Term Assets	$29.25M	$35.62M	$29.02M
Total Long-Term Assets	$27.46M	$27.57M	$89.80M
Total Assets	$56.71M	$63.18M	$118.8M
YoY Change	-55.91%	-46.82%	37.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.903M	$3.985M	$2.929M
YoY Change	28.1%	36.06%	-11.15%
Accrued Expenses	$6.202M	$6.323M	$5.724M
YoY Change	-13.59%	10.47%	140.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.400M	$1.100M
YoY Change	-100.0%	27.27%	450.0%
Long-Term Debt Due	$5.008M	$1.159M	$2.243M
YoY Change	267.91%	-48.34%	180.37%
Total Short-Term Liabilities	$22.36M	$18.46M	$17.46M
YoY Change	36.9%	5.73%	98.75%
LONG-TERM LIABILITIES
Long-Term Debt	$3.644M	$7.493M	$12.76M
YoY Change	-73.29%	-41.27%	235.71%
Other Long-Term Liabilities	$508.6K	$432.8K	$930.4K
YoY Change	-85.33%	-53.48%	46.51%
Total Long-Term Liabilities	$4.152M	$7.925M	$13.69M
YoY Change	-75.73%	-42.1%	-49.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.36M	$18.46M	$17.46M
Total Long-Term Liabilities	$4.152M	$7.925M	$13.69M
Total Liabilities	$31.68M	$30.60M	$68.85M
YoY Change	-49.46%	-55.55%	90.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$391.9M	-$384.1M	-$310.4M
YoY Change	19.66%	23.73%	24.15%
Common Stock	$5.927K	$59.12K	$39.42K
YoY Change	-89.31%	49.97%	37.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$707.6K	$707.6K	$705.7K
YoY Change	0.27%	0.27%	0.0%
Treasury Stock Shares	11.00K shares	110.0K shares
Shareholders Equity	$6.050M	$13.66M	$50.40M
YoY Change
Total Liabilities & Shareholders Equity	$56.71M	$63.18M	$118.8M
YoY Change	-55.91%	-46.82%	37.53%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$7.885M	-$12.05M	-$19.19K
YoY Change	45939.76%	62691.45%	40.24%
Depreciation, Depletion And Amortization	-$490.0K	$740.0K	$600.0K
YoY Change	-175.38%	23.33%	36.36%
Cash From Operating Activities	-$6.550M	-$8.028M	-$14.24M
YoY Change	-13.7%	-43.62%	26.54%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$1.045M	$344.5K
YoY Change	-97.95%	203.26%	-72.21%
Acquisitions
YoY Change
Other Investing Activities	-$640.0K	$0.00	$7.050M
YoY Change	-78.74%	-100.0%
Cash From Investing Activities	-$660.0K	-$1.045M	$6.704M
YoY Change	-85.23%	-115.58%	-640.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$6.349M	$0.00
YoY Change
Cash From Financing Activities	-520.0K	$14.18M	$7.493M
YoY Change	-101.78%	89.25%	-2.93%
NET CHANGE
Cash From Operating Activities	-6.550M	-$8.028M	-$14.24M
Cash From Investing Activities	-660.0K	-$1.045M	$6.704M
Cash From Financing Activities	-520.0K	$14.18M	$7.493M
Net Change In Cash	-7.730M	$5.108M	-$42.78K
YoY Change	-145.26%	-12040.7%	-99.1%
FREE CASH FLOW
Cash From Operating Activities	-$6.550M	-$8.028M	-$14.24M
Capital Expenditures	-$30.00K	$1.045M	$344.5K
Free Cash Flow	-$6.520M	-$9.073M	-$14.58M
YoY Change	6.36%	-37.79%	16.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2016Q1	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2016Q1	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	USD
CY2016Q1	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	USD
CY2015Q1	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2016Q1	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2015Q1	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	500000	USD
CY2016Q1	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	1300000	USD
CY2015Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	3214033	shares
CY2016Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	4605473	shares
CY2016Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	1400000	shares
CY2016Q1	clbs	Debt Instrument Maximum Payment To Lender Based On Receipt Of Proceeds From Eligible Events DebtInstrumentMaximumPaymentToLenderBasedOnReceiptOfProceedsFromEligibleEvents	3000000	USD
CY2015Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1205775	USD
CY2016Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-127410	USD
CY2016Q1	clbs	Number Of Consecutive Days Share Price Under One Dollar NumberOfConsecutiveDaysSharePriceUnderOneDollar	P30D
CY2016Q1	clbs	Number Of Consecutive Trading Days Required Above One Dollar NumberOfConsecutiveTradingDaysRequiredAboveOneDollar	P10D
CY2016Q1	clbs	Number Of Days After The Initial Period To Meet Consecutive Trading Day Requirement NumberOfDaysAfterTheInitialPeriodToMeetConsecutiveTradingDayRequirement	P180D
CY2016Q1	clbs	Period In Which To Meet Consecutive Trading Day Threshold PeriodInWhichToMeetConsecutiveTradingDayThreshold	P180D
CY2015Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2016Q1	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2015Q1	clbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	1873	USD
CY2016Q1	clbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	0	USD
CY2016Q1	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	4605473	shares
CY2016Q1	clbs	Subsidiary Ownership Interest By Parent SubsidiaryOwnershipInterestByParent	0.801
CY2016Q1	clbs	Warrants Canceled WarrantsCanceled	27000	shares
CY2016Q1	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2016Q1	clbs	Warrants Expired WarrantsExpired	0	shares
CY2016Q1	clbs	Warrants Granted WarrantsGranted	1418440	shares
CY2015Q1	clbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	3.61
CY2016Q1	clbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	0.57
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	14.50
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	9.80
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.00
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	0.00
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	1.00
CY2015	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P1Y3M4D
CY2016Q1	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P1Y3M22D
CY2016Q1	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P1Y3M22D
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2016Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6323000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	480700	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	264200	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	486	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396496341	USD
CY2015Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	13.72
CY2016Q1	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	9.80
CY2016Q1	clbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	9.80
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59033464	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Caladrius Biosciences, Inc.
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4107388	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3984710	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2566101	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2612832	USD
CY2015Q1	us-gaap	Accretion Expense AccretionExpense	29724	USD
CY2016Q1	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6198488	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6322955	USD
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6198400	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	398423589	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3715700	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	851200	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	142500	USD
CY2015Q4	us-gaap	Assets Assets	57205295	USD
CY2016Q1	us-gaap	Assets Assets	63184946	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	29272432	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	35617964	USD
CY2016Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1409000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	6874800	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1409000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis	1409000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1409000	USD
CY2016Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2015Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	550000	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2015Q4	us-gaap	Cash Cash	6875600	USD
CY2016Q1	us-gaap	Cash Cash	1409000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19174061	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19131285	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20318411	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25426166	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-42776	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5107755	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.00
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56733012	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59123260	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56733012	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59123260	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	56733	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	59123	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19188225	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11981403	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-44592	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-66879	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-19232817	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12048282	USD
CY2015Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	0.01	shares
CY2016Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	0.01	shares
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	3368612	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	6228256	USD
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	2911743	USD
CY2016Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	3986178	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5345225	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5638649	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	932662	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	604440	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	737158	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	986040	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	800	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2771200	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	3148800	USD
CY2016Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.199
CY2015Q4	us-gaap	Fair Value Estimate Not Practicable Investments FairValueEstimateNotPracticableInvestments	6875600	USD
CY2016Q1	us-gaap	Fair Value Estimate Not Practicable Investments FairValueEstimateNotPracticableInvestments	1409000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2822100	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2964600	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	27900	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	427500	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	570000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	570000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	570000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	570000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5700000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5700000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2877900	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2735400	USD
CY2015Q4	us-gaap	Goodwill Goodwill	7013315	USD
CY2016Q1	us-gaap	Goodwill Goodwill	7013315	USD
CY2015Q4	us-gaap	Goodwill Gross GoodwillGross	7000000	USD
CY2016Q1	us-gaap	Goodwill Gross GoodwillGross	7000000	USD
CY2015Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2016Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	591307	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-44592	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-66879	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19184855	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11994418	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46633	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53378	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1144356	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46730	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-46633	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-53378	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1171699	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3069840	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1054362	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1074435	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	61711	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18463711	USD
CY2016Q1	us-gaap	Long Term Debt LongTermDebt	10600000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4171456	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-81754	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-52331	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	116610	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2877880	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2735380	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	550964	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	926817	USD
CY2016Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	300000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	372550	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	973729	USD
CY2015Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3715759	USD
CY2016Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	851246	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	33921471	USD
CY2016Q1	us-gaap	Liabilities Liabilities	30601951	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57205295	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63184946	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21015223	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1158799	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	4700000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5300000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	600000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10828544	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7492555	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	583041	USD
CY2016Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	450427	USD
CY2015Q4	us-gaap	Marketable Securities Restricted Current MarketableSecuritiesRestrictedCurrent	6875600	USD
CY2016Q1	us-gaap	Marketable Securities Restricted Current MarketableSecuritiesRestrictedCurrent	1409000	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	-429709	USD
CY2016Q1	us-gaap	Minority Interest MinorityInterest	-478773	USD
CY2016Q1	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	3100000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7493021	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14180880	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6704470	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1044827	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14240267	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8028298	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19186896	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11980917	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1096991	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	960200	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-486	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-921132	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	1800000	USD
CY2016Q1	us-gaap	Notes Payable NotesPayable	1800000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1192666	USD
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1358598	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	21260143	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	18562765	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18087864	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11073286	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6408200	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	989400	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1035900	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1865800	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1556900	USD
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	221500000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2946500	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2910000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	976768	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	894524	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1329	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1329	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-486	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1329	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-486	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	562001	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	432802	USD
CY2015Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2016Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	2776416	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-546027	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5685	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	344530	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1044827	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	818004	shares
CY2015Q1	us-gaap	Profit Loss ProfitLoss	-19231488	USD
CY2015Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	340270	USD
CY2016Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	368615	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7049000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-12047796	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17064900	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16923763	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2016Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	19400000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3476177	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3592788	USD
CY2015Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2016Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	19400000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11700000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7411828	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1096208	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6348646	USD
CY2015Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	259077	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	335297	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6803632	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5876178	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-372132490	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384113407	USD
CY2015Q1	us-gaap	Revenues Revenues	3172279	USD
CY2016Q1	us-gaap	Revenues Revenues	7489479	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11087899	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6458331	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4605473	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	202700	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	189300	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	52400	USD
CY2016Q1	us-gaap	Share Price SharePrice	1.00
CY2016Q1	us-gaap	Share Price SharePrice	0.705
CY2016Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	983828	shares
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7411828	USD
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1096208	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2955800	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	562800	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3715759	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	851245	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	23713533	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	13661768	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58073789	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	49968559	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23283824	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13182995	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	109989	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	109989	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37594894	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57380438	shares

Files In Submission

Name	View Source	Status
0000320017-16-000115-index-headers.html	Edgar Link	pending
0000320017-16-000115-index.html	Edgar Link	pending
0000320017-16-000115.txt	Edgar Link	pending
0000320017-16-000115-xbrl.zip	Edgar Link	pending
clbs-10qx20160331.htm	Edgar Link	pending
clbs-20160331.xml	Edgar Link	completed
clbs-20160331.xsd	Edgar Link	pending
clbs-20160331_cal.xml	Edgar Link	unprocessable
clbs-20160331_def.xml	Edgar Link	unprocessable
clbs-20160331_lab.xml	Edgar Link	unprocessable
clbs-20160331_pre.xml	Edgar Link	unprocessable
clbs-ex311_20160331xq1.htm	Edgar Link	pending
clbs-ex312_20160331xq1.htm	Edgar Link	pending
clbs-ex321_20160331xq1.htm	Edgar Link	pending
clbs-ex322_20160331xq1.htm	Edgar Link	pending
exhibit101unitpurchaseagre.htm	Edgar Link	pending
exhibit102operatingagreeme.htm	Edgar Link	pending
exhibit103technologylicens.htm	Edgar Link	pending
exhibit104clbspretiagreeme.htm	Edgar Link	pending
exhibit105pctpretiagreement.htm	Edgar Link	pending
exhibit106thirdamoxford.htm	Edgar Link	pending
exhibit107securitiespurcha.htm	Edgar Link	pending
exhibit108registrationrigh.htm	Edgar Link	pending
exhibit41formofwarrant.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2016 Q2 Form 10-Q Financial Statement

#000032001716000115 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2016 Q2 Form 10-Q Financial Statement

#000032001716000115 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta